KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Basic) (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EPS (Basic) for 7 consecutive years, with $0.24 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 140.0% year-over-year to $0.24, compared with a TTM value of $0.58 through Sep 2025, up 514.29%, and an annual FY2024 reading of $0.04, up 107.41% over the prior year.
  • EPS (Basic) was $0.24 for Q3 2025 at Aurinia Pharmaceuticals, up from $0.16 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.24 in Q3 2025 and bottomed at -$0.4 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.11, with a median of -$0.09 recorded in 2023.
  • The sharpest move saw EPS (Basic) tumbled 73.91% in 2021, then surged 1500.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.25 in 2021, then rose by 28.0% to -$0.18 in 2022, then fell by 0.0% to -$0.18 in 2023, then soared by 105.56% to $0.01 in 2024, then skyrocketed by 2300.0% to $0.24 in 2025.
  • Business Quant data shows EPS (Basic) for AUPH at $0.24 in Q3 2025, $0.16 in Q2 2025, and $0.17 in Q1 2025.